ceftibuten


Also found in: Medical, Wikipedia.

cef·ti·bu·ten

 (sĕf-tī′byo͞o-tn)
n.
A broad-spectrum cephalosporin antibiotic, C15H14N4O6S2, used primarily to treat ear and respiratory infections.

[cef(a)- + t(h)i(azole) + buten(e).]
References in periodicals archive ?
The Company also announced that C-Scape is an oral combination of ceftibuten, an approved third generation cephalosporin, and clavulanate, an approved beta-lactamase inhibitor.
double dagger]) Per 10% increase in cephalosporin prescribing during the previous year; includes cefaclor, cefadroxil, cefdinir, cefditoren pivoxil, cefixime, cefpodoxime proxetil, cefprozil, ceftibuten, cefuroxime axetil, cephalexin, cephradine, and loracarbef.
2000): Spectrum of antibiogram against pathogens related to respiratory infarction with special reference to ceftibuten.
He received incision and drainage, intravenous clindamycin for 3 days, and a 10 days course of oral ceftibuten.
17) Amoxicillin, amoxicillin-clavulanate and ceftibuten have been evaluated in separate clinical trials, but none has been clearly shown to have significant advantage over any other.
Las cefalosporinas de tercera generacion, tales como cefpodoxime proxetil o ceftibuten, son una alternativa a las fluoroquinolonas; sin embargo, los estudios disponibles han demostrado equivalencia en la eficacia clinica pero no microbiologica con la ciprofloxacina (nivel de evidencia IB).
Not included in the table are cefixime and ceftibuten because these agents are not satisfactorily effective against penicillin-nonsusceptible S.
Comparison of the efficacy of ceftibuten and norfloxacin in the treatment of acute gastrointestinal infection in children.
The newest cephalosporin, ceftibuten, has an extended half-life allowing once-a-day dosing.
Pernix or the Company), a specialty pharmaceutical company, today announced the sale of a non-core product, Cedax (ceftibuten capsules and ceftibuten for oral suspension), a third-generation cephalosporin antibiotic for the treatment of acute bacterial exacerbations of chronic bronchitis and middle ear infection, to SI Pharmaceuticals, LLC, for $2 million in gross cash proceeds.
09); 8 of the cephalosporins evaluated in the meta-analysis (cephalexin, cefadroxil, cefuroxime, cefpodoxime, cefprozil, cefixime, ceftibuten, and cefdinir) showed higher bacterial cure rates compared with penicillin.